Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Cancer Research to Benefit from Development of a Whole-Genome, Cancer-Specific Microarray

By BiotechDaily International staff writers
Posted on 14 Mar 2013
An agreement between a British biotech company and an American-based genomic research consortium paves the way for the development of a whole-genome, cancer-specific microarray.

The biotech company Oxford Gene Technology (Oxford, United Kingdom) will design the microarray for the Cancer Cytogenomics Microarray Consortium (New Orleans, LA, USA). The array will incorporate probes for over 500 cancer genes and 130 cancer-associated genomic regions for hematological and solid tumors. The aim is to improve cancer research through the accurate identification of DNA copy number changes, and loss of heterozygosity associated with different cancer types.

Oxford Gene Technology was chosen following the recent development and commercialization of its CytoSure Haematological Cancer +SNP Array, which targets the four common hematological cancers: chronic lymphocytic leukemia, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndrome.

The CytoSure Haematological Cancer +SNP array combines long oligo array comparative genomic hybridization probes for superior copy number detection with fully research-validated single nucleotide polymorphism (SNP) content for accurate identification of loss of heterozygosity without concurrent changes in gene copy number. The array content has been optimized to target regions known to be important in hematological cancers while providing good backbone coverage. CytoSure Interpret Software, which accompanies all CytoSure arrays, is a powerful, easy-to-use package for the analysis of copy number variation (CNV) and SNP data. Innovative features enable the automation of data analysis workflows, minimizing the need for user intervention and maximizing the consistency and speed of data interpretation.

The Cancer Cytogenomics Microarray Consortium (New Orleans, LA, USA) was formed in August 2009 by a group of clinical cytogeneticists, molecular geneticists, and molecular pathologists, who were interested in applying microarray technologies to cancer diagnosis and cancer research. The mission of the consortium is to promote communication and collaboration among cancer cytogenomics laboratories. The specific goals are to (1) establish platform-neutral and cancer specific microarray designs for diagnostic purposes, (2) share cancer microarray data between participating institutions for education purposes, (3) create a public cancer array database, and (4) carry out multicenter cancer genome translational research. Today, the consortium has grown to include more than 300 members from over 150 organizations in the US, Canada, and in other countries.

“The use of microarray technology will substantially improve the facility of cytogenetics research laboratories to identify cancer,” said Dr. M. Anwar Iqbal, president of the Cancer Cytogenomics Microarray Consortium. “The Cancer Cytogenomics Microarray Consortium board appreciates the efforts of companies such as Oxford Gene Technology to making the Cancer Cytogenomics Microarray Consortium cancer array design available to the cytogenetics research community worldwide.”

Related Links:

Oxford Gene Technology
Cancer Cytogenomics Microarray Consortium



RANDOX LABORATORIES
BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.